Veklury — Total revenues
Gilead Sciences Veklury — Total revenues decreased by 31.8% to $144.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 52.3%, from $302.00M to $144.00M. Over 3 years (FY 2022 to FY 2025), Veklury — Total revenues shows a downward trend with a -38.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates higher market adoption or demand for the therapy, while a decrease often reflects reduced clinical need or the impact of competitive alternatives in the infectious disease market.
Detailed definition
This metric represents the total net sales generated from a specific antiviral therapeutic product line within the compa...
Peer comparison
Similar to product-specific revenue metrics in other pharmaceutical companies, such as sales of individual blockbuster drugs or pandemic-related therapeutics, which are often sensitive to external health crises and seasonal demand.
gild_segment_veklury_total_revenuesHistorical Data
| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $976.25M | $976.25M | $976.25M | $976.25M | $546.00M | $546.00M | $546.00M | $546.00M | $555.00M | $214.00M | $692.00M | $338.00M | $302.00M | $121.00M | $277.00M | $211.00M | $144.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -44.1% | +0.0% | +0.0% | +0.0% | +1.6% | -61.4% | +223.4% | -51.2% | -10.7% | -59.9% | +128.9% | -23.8% | -31.8% |
| YoY Change | — | — | — | — | -44.1% | -44.1% | -44.1% | -44.1% | +1.6% | -60.8% | +26.7% | -38.1% | -45.6% | -43.5% | -60.0% | -37.6% | -52.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Gilead Sciences's veklury — total revenues?
- Gilead Sciences (GILD) reported veklury — total revenues of $144.00M in Q1 2026.
- How has Gilead Sciences's veklury — total revenues changed year-over-year?
- Gilead Sciences's veklury — total revenues decreased by 52.3% year-over-year, from $302.00M to $144.00M.
- What is the long-term trend for Gilead Sciences's veklury — total revenues?
- Over 3 years (2022 to 2025), Gilead Sciences's veklury — total revenues has grown at a -38.4% compound annual growth rate (CAGR), from $3.91B to $911.00M.
- What does veklury — total revenues mean?
- The total revenue generated from sales of the company's specific antiviral medication.